FDA & Prescription Drugs

• 'Sneak Attack' on Patients' Legal Rights

  Staff Writer | March 06, 2006 9:14 PM | 0 CommentsDenver, CO

  According to consumer watchdog Public Citizen, the FDA's new Drug Label Rule Fails to Guarantee Access to Vital Information and Includes 'Sneak Attack' on Patients' Legal Rights. Following is an excerpt from a recent Public Citizen's article:"It is time to end the double standard where doctors and other health professionals are informed by FDA-approved labeling, but patients are treated like...

• Therapeutic Vaccines

  Staff Writer | February 14, 2006 1:10 PM | 0 CommentsDenver, CO

  There is an interesting article on the promises of therapeutic vaccines at www.pharmaceutical-business-review.comAfter defining therapeutic vaccines, the article states that vaccine development is presently weighted towards cancer vaccines then outlines a history of failures in the vaccine industry. The author identifies two basic types of therapeutic vaccines described as personalized or...

• Doctors Back Ban on Gifts From Drug Makers

  Staff Writer | February 14, 2006 12:06 PM | 0 CommentsDenver, CO

  In the January 25 issue of the Journal of the American Medical Association, a group of influential doctors supports the banning of gifts, drugs and continuing education provided to medical professionals by pharmaceutical companies. The doctors claim that accepting these perks undermines patient care.According to Federal regulations, companies are not allowed to pay medical professionals to...

• Possible Black box warnings and medication guides for ADHD Drugs

  Staff Writer | February 10, 2006 6:20 PM | 0 CommentsDenver, CO

  The FDA Advisory Committee published an alert today regarding possible black box warnings and medication guides for ADHD Drugs.Attention deficit/hyperactivity drugs should be prescribed with a medication guide warning of potential cardiovascular risks with the class of stimulant agents, FDA's Drug Safety & Risk Management Advisory Committee recommended Feb. 9.FDA conducted an analysis of adverse...

• FDA Panel approves over-the-counter diet pill

  Staff Writer | February 01, 2006 6:42 PM | 0 CommentsDenver, CO

  Fat-blocking Orlistat may become first non-prescription weight-loss drug.As reported by the Associated Press, WASHINGTON - Federal health advisers have voted to recommend over-the-counter sales of a weight-loss pill now sold only with a prescription.Read more about Orlistat.

• The newest COX-2 pain reliever in Europe

  Staff Writer | February 01, 2006 6:00 PM | 0 CommentsDenver, CO

  The UK is first in the European market where Prexige (lumiracoxib) is available.Read the full Prexige article.

• Investigational Treatment for Alzheimer's--Axonyx

  Staff Writer | February 01, 2006 5:49 PM | 0 CommentsDenver, CO

  According to pharmaceutical-business-review.com, an online journal, we can anticipate a study of the potential of this drug in treating Alzheimers in the not too distant future.Read more about the investigational treatment of Axonyx.

• Vioxx: Merck facing hundreds of lawsuits

  Staff Writer | February 01, 2006 5:41 PM | 0 CommentsDenver, CO

  Merck is facing hundreds of lawsuits from people who took Vioxx before it was pulled from the market in September 2004, when a study showed it could double risk of heart attack or stroke if taken for 18 months or longer. However, Merck said no such risk has been shown for shorter periods.This story can be found at: Vioxx Lawsuit